Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy Meeting Abstract


Authors: Wong, J. L.; Knorr, D.; Whiting, K.; Seshan, V. E.; Pietzak, E. J.; Donahue, T. F.; Cha, E. K.; Goh, A. C.; Smith, R.; Dalbagni, G.; McGill, M.; Hernandez, C.; McCarter, M.; Rosenberg, J. E.; Bochner, B. H.
Abstract Title: Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy
Meeting Title: 2022 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 16 Suppl.
Meeting Dates: 2022 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-06-01
Language: English
ACCESSION: WOS:000863680304968
PROVIDER: wos
DOI: 10.1200/JCO.2022.40.16_suppl.TPS4616
Notes: Meeting Abstract: TPS4616 -- Meeting also held virtually -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Venkatraman Ennapadam Seshan
    382 Seshan
  2. Guido Dalbagni
    325 Dalbagni
  3. Robert C Smith
    8 Smith
  4. Bernard Bochner
    468 Bochner
  5. Jonathan Eric Rosenberg
    513 Rosenberg
  6. Timothy Francis Donahue
    72 Donahue
  7. Eugene K. Cha
    100 Cha
  8. Eugene J Pietzak
    116 Pietzak
  9. Alvin Chun chin Goh
    73 Goh
  10. David A Knorr
    22 Knorr
  11. Jeffrey L Wong
    9 Wong
  12. Marlena Rose McGill
    24 McGill
  13. Karissa A. Whiting
    47 Whiting